On April 2, 2019, Fusion Pharmaceuticals announced a US$105 million Series B financing led by health investor, OrbiMed Advisors and medical-technology company Varian Medical Systems. The proceeds will allow Fusion Pharmaceuticals to expand its team and build out the clinical program in targeted alpha therapeutics, and accelerate a pipeline of new radiopharmaceuticals and combination therapy strategies.
Fusion Pharmaceuticals is a biopharmaceutical company that develops targeted alpha-particle radiotherapeutics for the treatment of chemotherapy resistant cancers.
Osler, Hoskin & Harcourt LLP represented Fusion Pharmaceuticals with a team led by Chad Bayne that included Michael Grantmyre, Sahil Chopra (Emerging and High Growth Companies), Paul Seraganian, Chad West (Tax), and Peter Glossop (Competition & Antitrust).
Key Contact
Partner, Emerging and High Growth Companies, Toronto
Team
Associate, Emerging and High Growth Companies, Toronto
Partner, Emerging and High Growth Companies, Calgary
